Fundraising Fox

Vividion Therapeutics

acquired by Bayer

Princeton, US · Founded 2013 · Delaware corporation · 5 known investors

vividion.com ↗

Vividion Therapeutics develops small molecule therapeutics using a covalent-first chemoproteomics approach to identify and target previously undruggable proteins. The company operates across the full drug development spectrum from discovery to clinical development.

AI & Machine LearningBiotechDeep Techin /vividion-therapeutics

Founders & leadership

BC
Ben CravattScientific Founder
PB
Phil BaranScientific Founder
JY
Jin-Quan YuScientific Founder
JP
John ParkExecutive Officer
JC
John ClarkeExecutive Officer, Director

Investors · 5

ARCH Venture PartnersChicago · $50K – $250Mvia Kristina Burow · board
Avoro Capital AdvisorsNew York
Cardinal PartnersPrinceton
Nextech InvestZurich · $648K – $3.2Mvia Benjamin Cravatt · board
Versant VenturesreportedSan Francisco · $250K – $5M

Reported raises · per SEC filings

Form D private placements
▶$135MraisedMar 2021 · 27 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jeffrey HatfieldExecutive Officer, Director
  • Patricia L. AllenExecutive Officer
  • Benjamin CravattDirector
  • Kristina BurowDirector
  • John ClarkeDirector
  • Richard HeymanDirector
  • Thomas E. DanielDirector
  • Thomas WoiwodeDirector
  • Jakob LovenDirector
Offering amount
$135M
Amount sold
$135M
First sale
Feb 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$82MraisedMay 2019 · 20 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Diego K. MirallesExecutive Officer, Director
  • Fred AslanExecutive Officer
  • Benjamin CravattDirector
  • Kristina BurowDirector
  • Jakob LovenDirector
  • Richard HeymanDirector
  • Tom DanielDirector
  • Thomas WoiwodeDirector
  • John ClarkeDirector
Offering amount
$82M
Amount sold
$82M
First sale
Apr 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$20.2MraisedJan 2017 · 8 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • John ParkExecutive Officer
  • Benjamin CravattDirector
  • John K. ClarkeExecutive Officer, Director
Offering amount
$50.5M
Amount sold
$20.2M
First sale
Jan 2017
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3.5MraisedApr 2016 · 1 investors · Biotechnology
Rule 506(c)
Officers, directors & promoters on the filing
  • John K. ClarkeExecutive Officer, Director
  • John ParkExecutive Officer, Director
  • Benjamin CravattDirector
Offering amount
$4M
Amount sold
$3.5M
Minimum investment
$1
First sale
Mar 2016
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06c
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news